Masterflex SE has met its forecast for the 2025 financial year according to preliminary figures, posting new record earnings while strengthening its financial position. Consolidated revenue rose to EUR 102.6 million, exceeding the previous year's level of EUR 98.1 million by 4.6%, within the forecast range of EUR 100 million to EUR 105 million. The operational performance developed positively despite a continuing challenging economic environment.
The company achieved record results with operating EBITDA increasing by 7.4% to EUR 19.5 million and operating EBIT rising 9.8% to EUR 14.0 million. EBIT reached EUR 13.7 million, within the forecast range of EUR 12 million to EUR 15 million. This resulted in a further increase in the operating EBIT margin to 13.6% compared with 13.0% in the previous year, despite currency losses and start-up costs for the new site in Morocco.
The US subgroup performed particularly well in 2025, while the medical technology area experienced dynamic demand growth. The share of high-margin medical technology in consolidated revenue increased from 18% in 2024 to 21% in the 2025 financial year. Despite economic headwinds particularly noticeable in Germany, demand in the industrial customer sectors grouped under "Tech" and in the trading business declined only moderately. The order backlog remained stable at EUR 19.8 million at year-end, in line with the previous year's level.
Masterflex significantly strengthened its financial position, with the equity ratio improving to 73.3% from 67.7% in the previous year. Financial liabilities were substantially reduced, with net debt falling to EUR 2.7 million from EUR 9.0 million. The debt ratio (net debt/EBITDA) improved significantly to 0.1 from 0.5 in the previous year.
Dr Andreas Bastin, CEO of Masterflex SE, commented that despite the challenging economic environment, the company met its forecasts, achieved solid revenue growth, and slightly increased profitability through continuous efficiency improvements. He noted particular satisfaction with the development of the medical technology business and further strengthening of the balance sheet, stating that building on this solid foundation positions the company well to continue its growth course in coming years.
The figures are still subject to confirmation by the auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and the 2026 forecast will be published on March 31, 2026, according to information available at www.newmediawire.com.
